Please assess the completion status of the following clinical trial:

Trial Title: Pramlintide Combined With Model Predictive Control Algorithm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least six months (the diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determination are not needed).~* Age 21 to 65 years~* For females, not currently known to be pregnant~* An understanding of the protocol and a willingness to follow it~* HbA1c between 7 and 9%~* Normal renal function (determined utilizing the comprehensive metabolic panel at screening with the Modification of Diet in Renal Disease (MDRD) formula and defined by estimated Glomerular Filtration Rate (eGFR) of ≥60 ml/min/1.73 m2.~* Hematocrit \>36 (females); \>38 (males)~Exclusion Criteria:~* Known hypersensitivity to SYMLIN or any of its components, including metacresol~* Poor compliance with current insulin regimen~* Poor compliance with prescribed self-blood glucose monitoring~* HbA1c \<7 or \>9%~* Severe hypoglycemia resulting in seizure or loss of consciousness in the 2 weeks prior to enrollment~* Active infection~* Current use of dietary supplements (subjects may be enrolled if they stop taking dietary supplements two weeks prior to admission and for the duration of their participation)~* Active gastroparesis~* Use of drugs that stimulate gastrointestinal motility (e.g. metoclopramide)~* Diabetic ketoacidosis in the past 3 months~* Current treatment for a seizure disorder~* Cystic fibrosis~* Asthma requiring hospitalization or treatment with oral steroids within the past year~* Presence of a uncontrolled adrenal disorder~* A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:~  * Inpatient psychiatric treatment in the past 6 months~ * Abnormal liver function (Transaminase \>2 times the upper limit of normal)~ * Heart failure~ * Coronary artery disease~ * Arrhythmia~ * Seizure disorder~ * Any carcinogenic disease~ * Creatinine concentration above the upper limit of normal for age and sex~ * Active coronary artery disease~ * Uncontrolled thyroid disease~ * Use or abuse of alcohol~ * Active kidney dialysis~ * If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study~ * Note: adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment~* Addison's disease~* Current use of a beta blocker medication~* Hematocrit \< 36 (female), \<38 (male)~* Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study~* Allergy to the sensor or to one of its components~* Continued use of acetaminophen.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Closed loop with pramlintide (Type: EXPERIMENTAL): Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
- Closed loop without pramlintide (Type: EXPERIMENTAL): This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
- Open loop with pramlintide (Type: EXPERIMENTAL): The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.

Based on this trial design, predict the completion outcome and termination type (if applicable).